The 52-year-old is cautiously optimistic about the new FDA-approved drug Radicava.
Research in Japan shows the drug slows muscle decline by 33 percent in people who were recently diagnosed with the disease. Frey may be an ideal candidate for infusions of the drug.
The New York Times reports the drug will cost about $145,000 a year. Health care professionals say they'll work quickly to get insurance companies to provide coverage.